Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Authors:
- Nabil AhmedNANabil Ahmed
- Vita S. BrawleyVBVita S. Brawley
- Meenakshi HegdeMHMeenakshi Hegde
- Catherine RobertsonCRCatherine Robertson
- Alexia GhaziAGAlexia Ghazi
- Claudia GerkenCGClaudia Gerken
- Enli LiuELEnli Liu
- Olga DakhovaODOlga Dakhova
- Aidin AshooriAAAidin Ashoori
- Amanda CorderACAmanda Corder
- Tara GrayTGTara Gray
- Meng-Fen WuMWMeng-Fen Wu
Top Cited Papers
- 20 May 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15) , 1688-1696
Abstract
Purpose: The outcome for patients with metastatic or recurrent sarcoma remains poor. Adoptive therapy with tumor-directed T cells is an attractive therapeutic option but has never been evaluated in sarcoma.Patients and Methods: We conducted a phase I/II clinical study in which patients with recurrent/refractory human epidermal growth factor receptor 2 (HER2) –positive sarcoma received escalating doses (1 × 104/m2to 1 × 108/m2) of T cells expressing an HER2-specific chimeric antigen receptor with a CD28.ζ signaling domain (HER2-CAR T cells).Results: We enrolled 19 patients with HER2-positive tumors (16 osteosarcomas, one Ewing sarcoma, one primitive neuroectodermal tumor, and one desmoplastic small round cell tumor). HER2-CAR T-cell infusions were well tolerated with no dose-limiting toxicity. At dose level 3 (1 × 105/m2) and above, we detected HER2-CAR T cells 3 hours after infusion by quantitative polymerase chain reaction in 14 of 16 patients. HER2-CAR T cells persisted for at least 6 weeks in seven of the nine evaluable patients who received greater than 1 × 106/m2HER2-CAR T cells (P = .005). HER2-CAR T cells were detected at tumor sites of two of two patients examined. Of 17 evaluable patients, four had stable disease for 12 weeks to 14 months. Three of these patients had their tumor removed, with one showing ≥ 90% necrosis. The median overall survival of all 19 infused patients was 10.3 months (range, 5.1 to 29.1 months).Conclusion: This first evaluation of the safety and efficacy of HER2-CAR T cells in patients with cancer shows the cells can persist for 6 weeks without evident toxicities, setting the stage for studies that combine HER2-CAR T cells with other immunomodulatory approaches to enhance their expansion and persistence.Keywords
This publication has 41 references indexed in Scilit:
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cellsBlood, 2012
- Cellular Immunotherapy for Soft Tissue SarcomasImmunotherapy, 2012
- Genetically Modified T cells Targeting Interleukin-11 Receptor α-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung MetastasesCancer Research, 2012
- Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcomaCancer Gene Therapy, 2011
- Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastomaBlood, 2011
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Expression of HER2/erbB-2 Correlates With Survival in OsteosarcomaJournal of Clinical Oncology, 1999